false
0001267565
0001267565
2026-08-12
2026-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 12, 2026
COLLEGIUM PHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
| Virginia |
|
001-37372 |
|
03-0416362 |
(State
or Other Jurisdiction
of Incorporation or Organization) |
|
(Commission
File Number) |
|
(IRS Employer Identification
No.) |
| 100 Technology Center Drive |
| Suite 300 |
| Stoughton, MA 02072 |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including
area code: (781) 713-3699
Securities registered pursuant to Section 12(b) of the Act:
| Title of
each class |
Trading Symbol(s) |
Name of each
exchange on which registered |
| Common stock, par value $0.001 per share |
COLL |
The NASDAQ Global Select Market |
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On August 12, 2026, Collegium Pharmaceutical, Inc. (“Collegium”
or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”)
with Jefferies LLC to repurchase $50 million of the Company’s common stock. The ASR Agreement was undertaken as part of the $150
million share repurchase program authorized by its Board of Directors in July 2025.
Under terms of the ASR Agreement, the Company will pay $50 million
to Jefferies LLC and will receive an initial delivery of 1,556,420 shares, based on the $25.70 closing stock price of Collegium’s
common stock on August 12, 2026, representing approximately 80% of the total shares the Company expects to repurchase under the ASR Agreement.
The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the
term of the ASR Agreement and subject to adjustments related to the terms and conditions of the ASR Agreement. The final settlement of
the ASR Agreement is expected to be completed no later than the fourth quarter of 2026. As of June 30, 2026, Collegium had approximately
32.5 million shares outstanding.
Forward-Looking Statements
To the extent that the information in this Current Report on Form 8-K
are not descriptions of historical facts regarding the Company, they are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company
may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Examples of forward-looking statements contained in this Form 8-K include, among others, statements
about the share repurchase program, the transactions under the ASR and the expected completion date of the ASR. Such statements are subject
to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ
materially from the Company's current expectations, including risks relating to, among others: developments or changes in the securities
markets and fluctuations in the trading volume and market price of the Company's common stock and other risks described under the heading
"Risk Factors" in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings
with the SEC. Any forward-looking statements that we make in this Form 8-K speak only as of the date of this Form 8-K. The Company
assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after
the date of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: August 13, 2026 |
Collegium Pharmaceutical, Inc. |
| |
|
|
| |
By: |
/s/ Colleen Tupper |
| |
|
Name: |
Colleen Tupper |
| |
|
Title: |
Executive Vice President and Chief Financial Officer |
